查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179913

2022-2029 年全球透皮給藥裝置市場

Global Transdermal Drug Delivery Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計在預測期內（2022-2029 年），透皮給藥裝置的全球市場規模將顯著增長。

藥物輸送設備是用於輸送藥物和治療劑的專用設備。 透皮藥物輸送裝置使用貼在皮膚上的含藥粘性皮膚貼劑，將規定量的藥物輸送到血流中。

市場動態

推動全球透皮貼劑市場發展的主要因素是世界上疾病數量的增加、研發成本的增加以及公眾對透皮貼劑益處的認識。 新產品發布的增加有助於透皮給藥裝置市場的增長。

預計透皮給藥系統應用的擴展和新研究數量的增加將推動市場增長。

採用這些透皮給藥裝置治療神經和心血管疾病等各種慢性疾病以及新產品的不斷推出正在推動透皮給藥裝置市場。我來了。 此外，世界上越來越多的疾病也在推動市場的增長。 許多醫療保健公司正在加緊研發活動以開發新產品。

之所以使用透皮給藥裝置，是因為它們優於其他給藥途徑，例如避免肝臟首過效應、降低給藥頻率和提高患者依從性。 由於各種疾病的增加，透皮治療貼劑的市場正在全球範圍內擴大。 此外，主要參與者增加對新型補丁和技術先進產品的研究和開發也有望在市場增長中發揮關鍵作用。

各種新產品的發布、監管批准和研究都為市場的增長做出了貢獻。 例如，2022年10月17日，專注於透皮療法開發的久光製藥全資子公司Noven Pharmaceuticals.Inc.榮獲第36屆美國精神獎在醫學護士協會 (APNA) 年會上宣布了兩個新藥代動力學 (PK) 建模數據集結果的展示。 這些數據旨在研究右苯丙胺透皮系統 (d-ATS) 在治療注意力缺陷多動障礙 (ADHD) 時的佩戴時間變化以及 d-ATS 從兒科患者到成人的療效。顯示了每個外推。

與透皮給藥裝置相關的限制預計會阻礙市場增長。

但是，透皮給藥貼劑的一個主要限制是它們是親脂性的，只能輸送少量藥物。 從皮膚最外層遞送高分子量（大於 500 道爾頓）和親水性藥物非常有限。 主動輸送系統可以擴大輸送範圍，但它們需要外部電源並且是笨重的設備。

如果產品被召回，在召回和更換有缺陷產品的過程中，公司和製造商可能會因更換或維修有缺陷的產品而蒙受巨大損失。 如此巨大的損失影響了公司的收入和市場份額，並影響了整個市場。 關鍵的挑戰與其說是技術本身，不如說是製藥和醫療器械這兩個不同領域的整合。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於各種研究和臨床試驗被推遲，透皮給藥裝置市場因 COVID 遭受了巨大損失。 迫切需要一種疫苗來防止 COVID 及其變種在世界範圍內傳播，並引起了人們的關注。 世界各地正在發生各種舉措、產品發布、創新、合作和合併，推動了市場的增長。 例如，2020年4月13日，Hisamitsu Pharmaceutical Co., Ltd.的全資子公司Noven Pharmaceuticals, Inc.獲得美國食品藥品監督管理局（FDA）批准用於治療精神分裂症患者。宣布其 SECUADO（阿塞那平）透皮系統現在可以在美國通過處方獲得。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

  • 市場影響因素
    • 司機
      • 擴展透皮給藥系統的應用領域
      • 新產品發布激增
      • 感染增加
    • 約束因素
      • 與透皮給藥裝置相關的限制
    • 商機
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 水庫補丁
  • 矩陣補丁
  • 含有藥物的貼片
  • 微針貼片

第8章技術

  • 被動透皮吸收技術
    • 化學增強劑
    • 前藥
    • 共晶系統
  • 透皮製劑技術
    • 射頻消融治療
    • 激光熱燒灼
    • 電穿孔
    • 離子導入
    • 微針
    • 噴射器
    • 超聲波

第 9 章按應用

  • 疼痛管理
  • 激素替代療法
  • 節育
  • 神經系統疾病
  • 吸煙門診
  • 心血管疾病
  • 糖尿病
  • 其他

第 10 章最終用戶

  • 醫院
  • 門診手術中心
  • 家庭護理

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • 諾華
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Zydus Lifesciences Ltd
  • Boehinger Ingelheim International GmbH
  • AbbVie（Allergan）
  • UCB S.A.
  • Viatris Inc.
  • Noven Pharmaceuticals, Inc.
  • Acrux Limited
  • Purdue Pharma L.P.
  • Endo International plc

第 14 章全球透皮給藥裝置市場-DataM

簡介目錄
Product Code: DMMD49

Market Overview

The global transdermal drug delivery devices market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Drug delivery devices are specialized equipment used for the delivery of a drug or therapeutic agent. A transdermal drug delivery device uses a medicated adhesive skin patch that is placed on the skin to deliver a specific dose of medication into the bloodstream.

Market- Dynamics

The major factors driving the global transdermal drug delivery devices market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding the advantages of transdermal drug delivery devices. An increase in novel product launches contributes to the growth of the transdermal drug delivery devices market.

The expanding areas of application of transdermal drug delivery systems and rising novel research studies are expected to drive the market's growth.

The rising adoption of these transdermal drug delivery devices for the treatment of various chronic diseases, such as neurological or cardiovascular disorders, and many more and the rising number of novel product launches drive the transdermal drug delivery devices market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

The transdermal drug delivery devices are used for the advantages it provides over other route of administration drug delivery such as avoiding hepatic first-pass effect reduced dosing frequency and better patient compliance. The market for these patches is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel patches and the availability of technologically advanced products by key players are also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals and research studies contribute to the market's growth. For instance, in October 17, 2022, Noven Pharmaceuticals. Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly owned subsidiary, focusing on the transdermal therapy development, announced about presenting its novel two pharmacokinetic (PK) modeling datasets results at the 36th annual conference of American Psychiatric Nurses Association (APNA). The data shows the investigation of dextroamphetamine transdermal system's (d-ATS) variable wear times for the Attention-Deficit/Hyperactivity Disorder (ADHD) treatment and d-ATS efficacy extrapolation from pediatric patients to adults respectively.

The limitations associated with transdermal drug delivery devices are expected to hamper the market's growth.

However, the major limitation of transdermal drug delivery patches is that they can deliver only lipophilic, small and low-dose drugs. The high molecular weight (more than 500 Dalton) and hydrophilic drug delivery via the skin's outermost layer are highly restrained. The active delivery system can enhance the extent of transmission, but it requires an external power supply, and the devices are bulky as well.

If a product is recalled, the process of retrieving and replacing the defective product may cause a company or a manufacturer to incur huge losses associated with replacing and fixing faulty products. These huge losses will affect the revenue and the company's market share, which will impact the overall market. The key challenges are less about the technology itself and more about integrating two distinct world's pharma and medical device.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transdermal drug delivery devices market has experienced huge losses due to COVID, as various research and clinical trials got postponed. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe diverted the attention. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in April 13, 2020, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly owned subsidiary, announced that its SECUADO (asenapine) transdermal system, approved for the treatment of schizophrenia patients by the U.S. Food and Drug Administration (FDA), is now available in the U.S. by prescription.

Segment Analysis

The micro-needle patch segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The micro-needle patch segment is the highest market holder in the global transdermal drug delivery devices market. The global transdermal drug delivery devices market is segmented based on product type: reservoir patch, matrix patch, drug-in adhesive patch and micro-needle patch. The micro-needle patch segment is the largest market shareholder due to its better advantage, efficacy and results, increasing diseases and rising adoption of these transdermal drug delivery devices.

In micro-needle patch with the sharp micro-needles (made up of ceramics and silicon) the skin tissues are pierced. As a result, there is a formation of micro-scale perforation. The perforated surface provides the pharmaceutical active ingredient passage. The micro-needle patch generally is categorized into four types: solid micro-needle, dissolving micro-needle, coated micro-needle, and hollow micro-needle patches. The solid ones are utilized as a pre-treatment for skin to develop micro-scale pores. In coated one micro-needle are directly applied to the skin, from the needle's surface the drug dissolves off and eventually transfers to the body. The dissolving micro-needles are the ones in which drugs are loaded in micro-needles formed of biodegradable polymer.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in December 2, 2022, Zydus Lifesciences Limited announced its approval for Estradiol Transdermal System USP marketing, by the United States Food and Drug Administration (USFDA). Estradiol is utilized for treating menopause symptoms like hot feelings in the neck and chest or strong feelings of heat and vaginal dryness in women. The drug will be produced at the formulation manufacturing site of Zydus Lifesciences at Ahmedabad, India.

Geographical Analysis

North America holds the largest market share in the global transdermal drug delivery devices market.

North America dominates the global transdermal drug delivery devices market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of products such as reservoir patch, matrix patch, drug-in adhesive patch, micro-needle patch, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the transdermal drug delivery devices market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2022, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly-owned subsidiary, announced that the approval of XELSTRYM (dextroamphetamine) transdermal system, CII from the U.S. Food and Drug Administration (FDA) for Attention-Deficit/Hyperactivity Disorder (ADHD) treatment for adults and pediatric patients. XELSTRYM is the only transdermal amphetamine patch which received FDA-approval.

Competitive Landscape

The transdermal drug delivery devices market is moderately competitive with local and global companies' presence. Novartis AG, Zydus Lifesciences Ltd, Boehinger Ingelheim International GmbH, AbbVie (Allergan), UCB S.A., Viatris Inc., Noven Pharmaceuticals, Inc., Acrux Limited, Purdue Pharma L.P., Endo International plc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in January 5, 20221, Endo International plc announced that Endo Ventures Limited, its subsidiary has entered into agreements with Radius Health, Inc. to commercialize and distribute abaloparatide in Canada. Under the agreement, Endo got the rights to abaloparatide-transdermal patch (abaloparatide-TD), a novel formulation currently undergoing clinical development.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

EXELON PATCH: Exelon Patch is a rivastigmine transdermal patch indicated for dementia of the Alzheimer's type (AD) and dementia linked with Parkinson's disease (PD).

The global transdermal drug delivery devices market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Expanding areas of application of transdermal drug delivery systems
      • 4.1.1.2. Surge in novel product launches
      • 4.1.1.3. Increasing incidence of infectious diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with transdermal drug delivery devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Reservoir Patch *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Matrix Patch
  • 7.4. Drug-in Adhesive Patch
  • 7.5. Micro-needle Patch

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Passive Transdermal Technology *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Chemical Enhancers
    • 8.2.4. Prodrug
    • 8.2.5. Eutectic Systems
  • 8.3. Active Transdermal Technology
    • 8.3.1. Radiofrequency Ablation
    • 8.3.2. Laser Thermal Ablation
    • 8.3.3. Electroporation
    • 8.3.4. Iontophoresis
    • 8.3.5. Microneedle
    • 8.3.6. Jet Injector
    • 8.3.7. Ultrasound

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Pain Management *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Hormone Replacement Therapy
  • 9.4. Contraception
  • 9.5. Neurological Disorders
  • 9.6. Smoking Cessation
  • 9.7. Cardiovascular Disorders
  • 9.8. Diabetes
  • 9.9. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Homecare Setting

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Novartis *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Zydus Lifesciences Ltd
  • 13.3. Boehinger Ingelheim International GmbH
  • 13.4. AbbVie (Allergan)
  • 13.5. UCB S.A.
  • 13.6. Viatris Inc.
  • 13.7. Noven Pharmaceuticals, Inc.
  • 13.8. Acrux Limited
  • 13.9. Purdue Pharma L.P.
  • 13.10. Endo International plc

LIST NOT EXHAUSTIVE

14. Global Transdermal Drug Delivery Devices Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and End-User
  • 14.3. Contact Us